Guardant Health Inc. GH, +2.46% shares fell in the extended session Monday after the cancer testing company announced a secondary offering of its stock. Guardant shares fell as much as 8% after hours, following a 2.5% rise to close the regular session at $30.80. The company said it plans to sell $250 million in shares with a 30-day option for an additional $37.5 million to cover overallotments. Underwriters include JP Morgan, Goldman Sachs, TD Cowen, and SVB Securities.
This article was originally published by Marketwatch.com. Read the original article here.
